Research programme: CD26 antigen antagonists - MGI GP
Alternative Names: Dipeptidyl peptidase IV anatagonists - MGI GP; DPP-IV antagonists - MGI GPLatest Information Update: 20 Feb 2008
At a glance
- Originator MGI GP
- Class Azetidines; Behavioural disorder therapies
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psychiatric disorders
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Psychiatric disorders in USA (unspecified route)
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma